TWI750393B - N-(2,6-二乙基苯基)-8-({4-[4-(二甲基胺基)六氫吡啶-1-基]-2-甲氧基苯基}胺基)-1-甲基-4,5-二氫-1H-吡唑并[4,3-h]喹唑啉-3-甲醯胺之新穎鹽類，其製備及含其之調配物 - Google Patents

N-(2,6-二乙基苯基)-8-({4-[4-(二甲基胺基)六氫吡啶-1-基]-2-甲氧基苯基}胺基)-1-甲基-4,5-二氫-1H-吡唑并[4,3-h]喹唑啉-3-甲醯胺之新穎鹽類，其製備及含其之調配物 Download PDF

Info

Publication number
TWI750393B
TWI750393B TW107122235A TW107122235A TWI750393B TW I750393 B TWI750393 B TW I750393B TW 107122235 A TW107122235 A TW 107122235A TW 107122235 A TW107122235 A TW 107122235A TW I750393 B TWI750393 B TW I750393B
Authority
TW
Taiwan
Prior art keywords
amino
pyrazolo
dihydro
compound
methyl
Prior art date
Application number
TW107122235A
Other languages
English (en)
Chinese (zh)
Other versions
TW201904971A (zh
Inventor
馬西摩 札派利
瑪麗娜 卡爾達瑞利
艾拉利亞 凱蒂安妮
馬提歐 德安妮羅
格曼諾 德阿拉斯摩
Original Assignee
義大利商那維諾醫療科學Ｓ Ｒ Ｌ 公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 義大利商那維諾醫療科學Ｓ Ｒ Ｌ 公司 filed Critical 義大利商那維諾醫療科學Ｓ Ｒ Ｌ 公司
Publication of TW201904971A publication Critical patent/TW201904971A/zh
Application granted granted Critical
Publication of TWI750393B publication Critical patent/TWI750393B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW107122235A 2017-06-29 2018-06-28 N-(2,6-二乙基苯基)-8-({4-[4-(二甲基胺基)六氫吡啶-1-基]-2-甲氧基苯基}胺基)-1-甲基-4,5-二氫-1H-吡唑并[4,3-h]喹唑啉-3-甲醯胺之新穎鹽類，其製備及含其之調配物 TWI750393B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305826 2017-06-29
EP17305826.4 2017-06-29

Publications (2)

Publication Number Publication Date
TW201904971A TW201904971A (zh) 2019-02-01
TWI750393B true TWI750393B (zh) 2021-12-21

Family

ID=59313166

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107122235A TWI750393B (zh) 2017-06-29 2018-06-28 N-(2,6-二乙基苯基)-8-({4-[4-(二甲基胺基)六氫吡啶-1-基]-2-甲氧基苯基}胺基)-1-甲基-4,5-二氫-1H-吡唑并[4,3-h]喹唑啉-3-甲醯胺之新穎鹽類，其製備及含其之調配物

Country Status (19)

Country Link
US (3) US11160806B2 (https=)
EP (1) EP3645535B1 (https=)
JP (1) JP7141416B2 (https=)
KR (1) KR102609333B1 (https=)
CN (1) CN110896636B (https=)
AR (1) AR112040A1 (https=)
AU (1) AU2018293729B9 (https=)
CA (1) CA3068357C (https=)
CL (1) CL2019003848A1 (https=)
EA (1) EA039764B1 (https=)
ES (1) ES2900048T3 (https=)
IL (1) IL271628B2 (https=)
MA (1) MA49498A (https=)
PL (1) PL3645535T3 (https=)
PY (1) PY1850855A (https=)
SG (1) SG11201912651WA (https=)
TW (1) TWI750393B (https=)
UY (1) UY37778A (https=)
WO (1) WO2019002454A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025002962A1 (en) 2023-06-30 2025-01-02 Nerviano Medical Sciences S.R.L. Use of a mps1 inhibitor for the treatment of hepatocellular carcinoma
WO2025021587A1 (en) 2023-07-21 2025-01-30 Nerviano Medical Sciences S.R.L. Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines

Also Published As

Publication number Publication date
EA202090115A1 (ru) 2020-05-25
EA039764B1 (ru) 2022-03-11
US11160806B2 (en) 2021-11-02
CA3068357C (en) 2022-04-19
JP2020525477A (ja) 2020-08-27
WO2019002454A1 (en) 2019-01-03
EP3645535B1 (en) 2021-09-08
PL3645535T3 (pl) 2022-03-21
JP7141416B2 (ja) 2022-09-22
CL2019003848A1 (es) 2020-07-10
KR20200020905A (ko) 2020-02-26
CN110896636A (zh) 2020-03-20
EP3645535A1 (en) 2020-05-06
US20200246339A1 (en) 2020-08-06
PY1850855A (es) 2019-04-01
AU2018293729B2 (en) 2022-03-10
AR112040A1 (es) 2019-09-11
CA3068357A1 (en) 2019-01-03
IL271628A (en) 2020-02-27
CN110896636B (zh) 2022-07-19
ES2900048T3 (es) 2022-03-15
UY37778A (es) 2019-01-31
KR102609333B1 (ko) 2023-12-01
MA49498A (fr) 2021-05-26
IL271628B2 (en) 2023-07-01
BR112019027924A2 (pt) 2020-08-18
US20240350501A1 (en) 2024-10-24
AU2018293729B9 (en) 2022-07-14
AU2018293729A1 (en) 2020-01-23
TW201904971A (zh) 2019-02-01
IL271628B1 (en) 2023-03-01
SG11201912651WA (en) 2020-01-30
US20220016122A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
CA2814581C (en) Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
CN111148745A (zh) Fgfr抑制剂的结晶形式及其制备方法
Sarmah et al. Mechanochemical synthesis of drug–drug and drug–nutraceutical multicomponent solids of olanzapine
AU2016355196A1 (en) Compounds and compositions useful for treating disorders related to NTRK
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
AU2016297754A1 (en) Compounds useful for treating disorders related to KIT and PDGFR
TW202540122A (zh) Ｋｒａｓ－ｇ１２ｄ之氮雜－四環氧氮呯抑制劑的多晶型物及合成方法
US20240350501A1 (en) SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT
CN113336774A (zh) 作为trk抑制剂的取代的手性二芳基大环化合物
BR112019027924B1 (pt) Fosfato de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2- metoxifenil}amino)-1-metil-4,5-di-hidro-1h-pirazolo[4,3-h]quinazolina-3- carboxamida, processo para a sua obtenção, composição farmacêutica, combinação e seus usos
HK40022862A (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
HK40022862B (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it